InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update [Yahoo! Finance]
InMed Pharmaceuticals Inc. - Common Shares (INM)
Company Research
Source: Yahoo! Finance
Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration Cash of $11.1M to support pharmaceutical developments into the fourth quarter of calendar year 2026 Vancouver, British Columbia--(Newsfile Corp. - September 23, 2025) - InMed Pharmaceuticals Inc. ( NASDAQ: INM ) (" InMed " or the " Company "), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced financial results for its fiscal year ending June 30, 2025 and provided a business update on its pharmaceutical drug development programs as well as the commercial segment for its wholly-owned subsidiary, BayMedica, LLC (" BayMedica The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2025, are available at www.inmedpharma.com and at www.sedar.com Eric A. Adams, InMed Chief Executive Officer, commented, "Throughout fiscal 2025,
Show less
Read more
Impact Snapshot
Event Time:
INM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INM alerts
High impacting InMed Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
INM
News
- InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901 [Yahoo! Finance]Yahoo! Finance
- InMed Pharmaceuticals GAAP EPS of -$8.36, revenue of $4.94M [Seeking Alpha]Seeking Alpha
- InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025GlobeNewswire
INM
Sec Filings
- 11/19/25 - Form 8-K
- 11/6/25 - Form 10-Q
- 11/3/25 - Form DEFA14A
- INM's page on the SEC website